Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Mar;19(3):241-251.
doi: 10.1080/1744666X.2023.2152330. Epub 2022 Nov 30.

A critical review of belumosudil in adult and pediatric patients with chronic graft-versus-host disease

Amandeep Salhotra  1 , Karamjeet Sandhu  1 , James O'Hearn  1 , Haris Ali  1 , Ryotaro Nakamura  1 , Badri G Modi  2
Affiliations
Review

A critical review of belumosudil in adult and pediatric patients with chronic graft-versus-host disease

Amandeep Salhotra et al. Expert Rev Clin Immunol. 2023 Mar.

Abstract

Introduction: Chronic graft-versus-host disease (cGVHD) is a complication of allogeneic hematopoietic cell transplantation (allo-HCT) and is the main cause of late non-relapse mortality (NRM). Three new agents are now approved to treat cGVHD, of which belumosudil has a unique and dual mechanism of action of i) targeting the Rho-GTPase-associated coiled-coil kinase 2 (ROCK2) in T helper follicular cells (TFH) and TH17 cells, this results in downregulation of proinflammatory cytokines (interleukin -21 and 17), the former in a STAT3-dependent mechanism, ii) inhibition of tissue fibrosis by targeting stress-induced polymerization of G-actin fibrils by inhibiting the Rho-ROCK-MRTF pathway.

Areas covered: In this review we describe the epidemiology of cGVHD, its cardinal symptoms, preventive and therapeutic options, including second-line approved therapies in the United States (US). Clinical trial data that led to approval of belumosudil is discussed, in addition to the clinical scenarios in which the approved drugs may be most applicable.

Expert opinion: Belumosudil is approved for treatment of adult and pediatric patients ≥ 12 years with cGVHD after failing two lines of therapy based on results of the ROCKstar study that showed high overall response rates (ORR), favorable adverse effect profiles, and low rates of severe infections. With the availability of three new agents for treatment of cGVHD, treating physicians have more therapeutic options for patients and have additional options of development new clinical trials using a combination of recently approved drugs.

Keywords: allogeneic HCT; belumosudil; cGVHD.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

LinkOut - more resources